Recardio Secures $3,000,000 Series A Funding Round

  • Feed Type
  • Date
    11/16/2015
  • Company Name
    Recardio
  • Mailing Address
    1 Market Street Spear Tower 36th Floor San Francisco, CA 94105 USA
  • Company Description
    RECARDIO (REgenerative CARDIOvascular Therapy) is an Austrian based life science company founded in 2011. It is focusing on drug based regenerative therapeutic modalities for the treatment of cardiovascular diseases.
  • Website
    http://www.recardio.eu
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $3,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The proceeds will be used to advance a Phase 2 clinical trial for Recardio’s lead therapeutic candidate, Dutogliptin, which is being developed for the treatment of acute myocardial infarction (AMI), commonly known as heart attack.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy